Wells Fargo Reiterates Buy Rating for Hinge Health, Inc.
Wells Fargo maintains its buy rating for Hinge Health, setting a $90 price target, a 19.78% upside from the current price.
Key Points
- Wells Fargo reiterated its buy rating for Hinge Health, Inc. (HNGE) with a $90 price target on June 24, 2026.
- Wells Fargo's $90 price target implies 19.78% upside from Hinge Health, Inc.'s ($HNGE) current $75.14 share price.
- Hinge Health shares traded at $70.38 on Wednesday, with a market cap of approximately $5.33 billion and a forward P/E of 20.6.
- Analysts broadly support Hinge Health with a consensus buy rating and a mean target price of $79.73.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Wells Fargo has reiterated its buy rating for Hinge Health, Inc. (NYSE:HNGE) on June 24, 2026, setting a price target of $90. Analyst Stan Berenshteyn maintained the rating, highlighting a continued positive outlook for the company.
Wells Fargo vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Hinge Health, Inc. Stock Down 14.0%
Shares of NYSE:HNGE traded around $70.38 on Wednesday. Hinge Health, Inc. has a market capitalization of about $5.33 billion, with a forward P/E ratio of 20.6, reflecting investor expectations of future earnings growth. The stock has seen a 52-week low of $30.08 and a high of $71.42. It has a 50-day moving average of $52.90 and a 200-day moving average of $47.85. The company's liquidity is supported by a current ratio of 1.303 and a quick ratio of 1.039, while its debt-to-equity ratio is 2.237.
$HNGE price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Hinge Health reported revenue of $646.34 million with a growth rate of 47.2%. However, the company is not yet profitable, with a net margin of -78.95% and a return on equity of -136.00%. The next earnings report is expected on August 4, 2026.
Insider Buying and Selling at Hinge Health, Inc.
On June 22, 2026, President James Pursley sold 33,000 shares at an average price of $69.31 as part of a planned transaction. Insight Holdings Group, LLC also had transactions on June 16, 2026, selling 65,581 shares at $70.36 in a planned sale, while another sale on the same day was not planned.
Analysts Set New Price Targets
On June 24, 2026, Wells Fargo maintained its buy rating with a $90 price target. Other analysts have also shown support: Baird maintained a hold with a $65 target on June 17, 2026, while Raymond James and Canaccord Genuity reiterated buy ratings with targets of $80 and $76, respectively, on June 15, 2026. The consensus among analysts is a buy recommendation, with a mean target price of $79.73 based on 15 opinions.
About Hinge Health, Inc.
Hinge Health, Inc. is a healthcare company based in San Francisco, California, that focuses on musculoskeletal system care. The company offers a platform that uses technology to automate and scale care delivery, addressing issues like acute injury, chronic pain, and post-surgical rehabilitation. Its services include AI-powered motion tracking and a wearable device for electrical nerve stimulation, primarily serving self-insured employers. Founded in 2012, the company is led by CEO Daniel A. Perez and employs approximately 1,437 people.
Bottom Line
Wells Fargo's reaffirmation of its buy rating for Hinge Health, Inc. underscores continued confidence in the company's growth potential. As a forward-looking statement, it's important for investors to consider that analyst ratings can change over time. Hinge Health remains a company to watch in the healthcare sector, particularly given its innovative approach to musculoskeletal care.
Get Hinge Health, Inc. alerts
New 13F filings, insider trades, and analyst moves on $HNGE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.